Pregled bibliografske jedinice broj: 31257
Prognostic significance of chromosome findings in patients with de-novo acute myelogenous leukaemia
Prognostic significance of chromosome findings in patients with de-novo acute myelogenous leukaemia // The Second Croatian Congress in Human Genetics Paediatr Croat 1998 42 Suppl 3 / Stavljenić-Rukavina, Ana (ur.).
Zagreb: Klinika za pedijatriju, Zagreb, 1998. str. 36-36 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 31257 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Prognostic significance of chromosome findings in patients with de-novo acute myelogenous leukaemia
Autori
Mrsić, Sanja ; Labar, Boris ; Mrsić, Mirando ; Nemet, Damir ; Bogdanić, Vinko ; Batinić, Drago ; Boban, Dubravka
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
The Second Croatian Congress in Human Genetics
Paediatr Croat 1998 42 Suppl 3
/ Stavljenić-Rukavina, Ana - Zagreb : Klinika za pedijatriju, Zagreb, 1998, 36-36
Skup
The Second Croatian Congress in Human Genetics
Mjesto i datum
Zagreb, Hrvatska, 21.10.1998. - 24.10.1998
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
acute myelogenous leukemia; cytogenetics; prognosis
Sažetak
From 1987. until 1995. 110 patients with de novo acute leukaemia were included into prospective study. Median age was 34 years (15-60). The majority of patients have AML-M2 (41%) or AML-M1 subtype (23%) according to FAB. Thirteen (12%) patients have AML-M3 subtype. AML-M4 was observed in 13 patients (12%) and AML-M5 in 9 patients (8%).In five patients (4%) a diagnosis of AML-M6 was established. Cytogenetic abnormalities were found in 79 (72%) patients. Thirty (27%) patients were classified as a good prognostic group, 43 pts. (39%) as a poor prognostic group, and 37 (34%) as intermediate group. Complete remission was obtained in 81% of patients with good karyotype, in 65% patients with intermediate karyotype and in only 37% in poor prognostic group (p=0.001). Probability of relapse for patients with poor karyotype is 82%, for intermediate group 68% and for patients with good karyotype 56% (p=0.05). In multivariate analysis older patients with poor karyotype, with AML-M4 or AML-M5 subtype, low number of platelets and/or high number of WBC at diagnosis have high probability of induction treatment failure and low probability of disease free survival.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
214006
Ustanove:
Klinički bolnički centar Zagreb
Profili:
Boris Labar
(autor)
Dubravka Boban
(autor)
Vinko Bogdanić
(autor)
Damir Nemet
(autor)
Drago Batinić
(autor)